Immunic Inc. traded at $1.11 this Wednesday April 15th, decreasing $0.07 or 5.93 percent since the previous trading session. Looking back, over the last four weeks, Immunic lost 4.31 percent. Over the last 12 months, its price rose by 17.77 percent. Looking ahead, we forecast Immunic Inc. to be priced at 1.14 by the end of this quarter and at 1.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.